The amyotrophic lateral sclerosis (ALS) treatment market involves drugs and therapies aimed at managing motor neuron damage and symptoms of ALS disease. ALS is a rare neurodegenerative disease affecting nerve cells in the brain and spinal cord. Some key drugs in the market are Rilutek, Radicava, and Edaravone. The ALS treatment drugs work by reducing glutamate levels, inhibiting neuronal death, and targeting oxidative stress and inflammation. The growing prevalence of ALS globally along with increased research and development activities are driving growth opportunities in this market.

The global amyotrophic lateral sclerosis treatment market is estimated to be valued at US$ 692.77 million in 2024 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023 to 2030.

Key Takeaways

Key players operating in the amyotrophic lateral sclerosis treatment are Orion Corporation, Bausch Health Companies Inc., CYTOKINETICS, INC., Aquestive Therapeutics, Inc., Sanofi ,Covis Pharma, Sun Pharmaceuticals Industries Ltd, Mitsubishi Tanabe Pharma Corporation, BrainStorm Cell Limited, ViroMed Co., Ltd, Ionis Pharmaceuticals, Genervon Biopharmaceuticals, LLC, Biogen, Orphazyme A/S, Apotex Inc, Neuralstem, Inc., Implicit Bioscience, F. Hoffmann-La Roche Ltd, AB Science, ADVANZ PHARMA.

The growing prevalence of ALS disease globally is expected to drive the demand for effective therapies over the forecast period. According to the ALS Association, around 5,000 new cases of ALS are diagnosed each year in the United States alone.

Technological advancements and increasing research and development activities are bringing novel therapies and treatment options into the ALS treatment market. Several biopharma companies are conducting clinical trials to evaluate new drug candidates targeting specific mechanisms of ALS progression.

Market Trends

Growing Drug Pipeline: There are over 25 drugs in various stages of clinical development for ALS treatment. Some potential drug candidates in advanced trials include Tofersen from Biogen targeting SOD1 gene mutation, and BIIB067 from Biogen targeting C9orf72 gene mutation ALS.

Combination Therapies: Researchers are exploring combination therapies using existing drugs along with new mechanisms. For instance, combining antioxidants like edaravone with riluzole to achieve better therapeutic outcomes.

Market Opportunities

Gene Therapy Approaches: Gene therapy is a promising approach to permanently correct genetic abnormalities causing certain forms of familial ALS. Several gene therapy clinical trials are ongoing.

Stem Cell Therapies: Mesenchymal stem cells and neuronal stem cells transplantation show potential in ALS treatment by protecting motor neurons from damage or replacing lost cells. More research is being conducted.

Europe currently holds the largest share in amyotrophic lateral sclerosis treatment market in terms of value. The high prevalence of ALS, strong healthcare infrastructure, and presence of leading drug manufacturers in the region support its dominance. North America also captures a significant market share due to rising government funding for disease research and advanced treatment facilities. Asia Pacific is projected to be the fastest growing regional market owing to increasing healthcare expenditure, growing patient population, and improving access to diagnosis and care. The emerging economies like India, China and Japan are expected to significantly contribute to the regional market growth in upcoming years.